An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease

Canadian Respiratory Journal

Volumn 13, Issue 8, 2006, Pages 415-420

  Ibrahim, Reda ^a   Granton, John T ^b   Mehta, Sanjay ^c  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Congenital heart disease; Endothelin; Hypoxia; Pulmonary hypertension

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; DIGOXIN; DIURETIC AGENT; HEMOGLOBIN; LIVER ENZYME; OXYGEN;

ADULT; ARTERIAL TRUNK; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ECHOCARDIOGRAPHY; EXERCISE TEST; FALLOT TETRALOGY; FEMALE; FUNCTIONAL ASSESSMENT; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; LIVER FUNCTION TEST; LUNG ATRESIA; MALE; MULTICENTER STUDY; OPEN STUDY; OXYGEN SATURATION; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PILOT STUDY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULSE RATE; REST; SHORT FORM 36; SIDE EFFECT; TRICUSPID VALVE ATRESIA; WALKING;

EID: 33846421617     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/746176     Document Type: Article

References (23)

1. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J 1958;46:755-62.
2. Granton JT, Rabinovitch M. Pulmonary arterial hypertension in congenital heart disease. Cardiol Clin 2002;20:441-57,vii.
3. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996;15:100-5.
4. Benisty JI, Landzberg MJ. Eisenmenger's Syndrome. Curr Treat Options Cardiovasc Med 1999;1:355-62.
5. Gildein HP, Wildberg A, Mocellin R. [Comparative studies of hemodynamics under prostacyclin and nifedipine in patients with Eisenmenger syndrome]. Z Kardiol 1995;84:55-63.
6. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858-65.
7. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series. Ann Intern Med 1999;130:740-3.
8. Adatia I, Haworth SG. Circulating endothelin in children with congenital heart disease. Br Heart J 1993;69:233-6.
9. Bando K, Vijayaraghavan P, Turrentine MW, et al. Dynamic changes of endothelin-1, nitric oxide, and cyclic GMP in patients with congenital heart disease. Circulation 1997;96:346-51.
10. Yoshibayashi M, Nishioka K, Nakao K, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 1991;84:2280-5.
11. Ishikawa S, Miyauchi T, Sakai S, et al. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. J Thorac Cardiovasc Surg 1995;110:271-3.
12. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Eng J Med 2002;346:896-903. (Erratum in 2002;346:1258).
13. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001;358:1119-23.
14. Christensen DD, McConnell ME, Book WM, Mahle WT. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol 2004;94:261-3.
15. Gatzoulis MA, Rogers P, Li W, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol 2005;98:147-51.
16. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Heart 2005;91:1447-52.
17. Schulze-Neick I, Gilbert N, Ewert R, et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: First open prospective multicenter study of bosentan therapy. Am Heart J 2005;150:716.
18. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(Suppl 12):5S-12S.
19. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-81.
20. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ 1993;2:217-27.
21. American Thoracic Society. ATS statement: Guidelines for the 6-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
22. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-92.
23. Berman EB, Barst RJ. Eisenmenger's syndrome: Current management. Prog Cardiovasc Dis 2002;45:129-38.